Great Point Partners LLC Iovance Biotherapeutics, Inc. Transaction History

Great Point Partners LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$16.33 - $33.07 $15.2 Million - $30.8 Million	-930,000 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$28.67 - $52.59 $360,467 - $661,214	12,573 Added 1.37%	930,000 $29.4 Million
Q4 2020 Feb 16, 2021	SELL	$28.04 - $50.26 $83 Million - $149 Million	-2,959,173 Reduced 76.33%	917,427 $42.6 Million
Q3 2020 Nov 16, 2020	BUY	$27.75 - $36.3 $4.21 Million - $5.5 Million	151,624 Added 4.07%	3,876,600 $128 Million
Q2 2020 Aug 14, 2020	BUY	$27.21 - $41.0 $36.4 Million - $54.8 Million	1,337,370 Added 56.01%	3,724,976 $102 Million
Q1 2020 May 15, 2020	SELL	$19.54 - $38.85 $51.3 Million - $102 Million	-2,627,569 Reduced 52.39%	2,387,606 $71.5 Million
Q4 2019 Feb 14, 2020	SELL	$17.95 - $29.41 $4.41 Million - $7.22 Million	-245,628 Reduced 4.67%	5,015,175 $139 Million
Q2 2019 Aug 14, 2019	SELL	$9.78 - $24.52 $3 Million - $7.52 Million	-306,545 Reduced 5.51%	5,260,803 $0
Q4 2018 Feb 15, 2019	BUY	$7.51 - $11.93 $15.6 Million - $24.7 Million	2,071,008 Added 59.23%	5,567,348 $49.3 Million
Q3 2018 Nov 14, 2018	BUY	$11.25 - $17.7 $119,193 - $187,531	10,595 Added 0.3%	3,496,340 $39.3 Million
Q2 2018 Aug 14, 2018	BUY	$12.45 - $16.95 $2.05 Million - $2.79 Million	164,572 Added 4.96%	3,485,745 $44.6 Million
Q1 2018 May 14, 2018	BUY	$8.1 - $19.5 $10.7 Million - $25.8 Million	1,321,173 Added 66.06%	3,321,173 $0
Q3 2017 Nov 14, 2017	BUY	$4.45 - $8.55 $8.9 Million - $17.1 Million	2,000,000	2,000,000 $15.5 Million

315

241M

3.77M

1.7M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.29B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Great Point Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Great Point Partners LLC with notifications on news.